Penumbra (PEN) to Release Earnings on Tuesday

Penumbra (NYSE:PEN) is projected to announce its earnings results after the market closes on Tuesday, February 18th. Analysts expect the company to announce earnings of $0.88 per share and revenue of $311.63 million for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Penumbra Stock Down 1.9 %

Shares of Penumbra stock opened at $267.83 on Friday. The company has a fifty day moving average price of $255.04 and a 200 day moving average price of $224.21. The company has a current ratio of 5.82, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02. Penumbra has a twelve month low of $148.00 and a twelve month high of $277.89. The stock has a market cap of $10.28 billion, a price-to-earnings ratio of 311.43, a price-to-earnings-growth ratio of 1.92 and a beta of 0.53.

Analysts Set New Price Targets

A number of analysts recently weighed in on PEN shares. Truist Financial upped their price target on shares of Penumbra from $240.00 to $285.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Citigroup upped their price objective on shares of Penumbra from $220.00 to $245.00 and gave the company a “neutral” rating in a research report on Wednesday, December 11th. BTIG Research upped their price objective on shares of Penumbra from $232.00 to $270.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. UBS Group initiated coverage on shares of Penumbra in a research report on Tuesday, January 21st. They issued a “buy” rating and a $305.00 price objective for the company. Finally, Needham & Company LLC reissued a “hold” rating on shares of Penumbra in a research report on Thursday, October 31st. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Penumbra has a consensus rating of “Moderate Buy” and an average target price of $261.36.

Insider Transactions at Penumbra

In other news, EVP Johanna Roberts sold 600 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $239.74, for a total transaction of $143,844.00. Following the transaction, the executive vice president now owns 64,044 shares of the company’s stock, valued at approximately $15,353,908.56. This trade represents a 0.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Adam Elsesser sold 15,000 shares of the stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $237.28, for a total transaction of $3,559,200.00. Following the sale, the chief executive officer now owns 852,582 shares in the company, valued at approximately $202,300,656.96. This trade represents a 1.73 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 33,819 shares of company stock valued at $8,129,483. Insiders own 5.00% of the company’s stock.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.